My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 406

    1.

    Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment.

    Glintborg D, Højlund K, Andersen M, Henriksen JE, Beck-Nielsen H, Handberg A.

    Diabetes Care. 2008 Feb;31(2):328-34. Epub 2007 Nov 13.PMID: 18000176 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Impaired insulin-stimulated phosphorylation of Akt and AS160 in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment.

    Højlund K, Glintborg D, Andersen NR, Birk JB, Treebak JT, Frøsig C, Beck-Nielsen H, Wojtaszewski JF.

    Diabetes. 2008 Feb;57(2):357-66. Epub 2007 Oct 31.PMID: 17977950 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome.

    Glintborg D, Hermann AP, Andersen M, Hagen C, Beck-Nielsen H, Veldhuis JD, Henriksen JE.

    Fertil Steril. 2006 Aug;86(2):385-97. Epub 2006 Jun 16.PMID: 16782094 [PubMed - indexed for MEDLINE]Related articles

    4.

    Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial.

    Aroda VR, Ciaraldi TP, Burke P, Mudaliar S, Clopton P, Phillips S, Chang RJ, Henry RR.

    J Clin Endocrinol Metab. 2009 Feb;94(2):469-76. Epub 2008 Nov 4.PMID: 18984667 [PubMed - indexed for MEDLINE]Related articles

    5.

    Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome.

    Berria R, Gastaldelli A, Lucidi S, Belfort R, De Filippis E, Easton C, Brytzki R, Cusi K, Jovanovic L, DeFronzo R.

    Clin Pharmacol Ther. 2006 Aug;80(2):105-14. Epub 2006 Jun 30.PMID: 16890572 [PubMed - indexed for MEDLINE]Related articles

    6.

    Pioglitazone treatment increases spontaneous growth hormone (GH) secretion and stimulated GH levels in polycystic ovary syndrome.

    Glintborg D, Støving RK, Hagen C, Hermann AP, Frystyk J, Veldhuis JD, Flyvbjerg A, Andersen M.

    J Clin Endocrinol Metab. 2005 Oct;90(10):5605-12. Epub 2005 Aug 2.PMID: 16076946 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome.

    Tarkun I, Cetinarslan B, Türemen E, Sahin T, Cantürk Z, Komsuoglu B.

    Eur J Endocrinol. 2005 Jul;153(1):115-21.PMID: 15994753 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment.

    Heutling D, Schulz H, Nickel I, Kleinstein J, Kaltwasser P, Westphal S, Mittermayer F, Wolzt M, Krzyzanowska K, Randeva H, Schernthaner G, Lehnert H.

    J Clin Endocrinol Metab. 2008 Jan;93(1):82-90. Epub 2007 Nov 6.PMID: 17986642 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome.

    Romualdi D, Guido M, Ciampelli M, Giuliani M, Leoni F, Perri C, Lanzone A.

    Hum Reprod. 2003 Jun;18(6):1210-8.PMID: 12773448 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Impaired insulin activation and dephosphorylation of glycogen synthase in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment.

    Glintborg D, Højlund K, Andersen NR, Hansen BF, Beck-Nielsen H, Wojtaszewski JF.

    J Clin Endocrinol Metab. 2008 Sep;93(9):3618-26. Epub 2008 Jun 10.PMID: 18544618 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial.

    Glintborg D, Andersen M, Hagen C, Heickendorff L, Hermann AP.

    J Clin Endocrinol Metab. 2008 May;93(5):1696-701. Epub 2008 Feb 19.PMID: 18285411 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Total and high molecular weight (HMW) adiponectin levels and measures of glucose and lipid metabolism following pioglitazone treatment in a randomized placebo-controlled study in polycystic ovary syndrome.

    Glintborg D, Frystyk J, Højlund K, Andersen KK, Henriksen JE, Hermann AP, Hagen C, Flyvbjerg A, Andersen M.

    Clin Endocrinol (Oxf). 2008 Feb;68(2):165-74. Epub 2007 Sep 4.PMID: 17803698 [PubMed - in process]Related articles

    13.

    Identification of the oxidized low-density lipoprotein scavenger receptor CD36 in plasma: a novel marker of insulin resistance.

    Handberg A, Levin K, Højlund K, Beck-Nielsen H.

    Circulation. 2006 Sep 12;114(11):1169-76. Epub 2006 Sep 4.PMID: 16952981 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Retinol-binding protein 4 in polycystic ovary syndrome--association with steroid hormones and response to pioglitazone treatment.

    Aigner E, Bachofner N, Klein K, De Geyter C, Hohla F, Patsch W, Datz C.

    J Clin Endocrinol Metab. 2009 Apr;94(4):1229-35. Epub 2009 Jan 21.PMID: 19158194 [PubMed - indexed for MEDLINE]Related articles

    15.

    Diet/Exercise versus pioglitazone: effects of insulin sensitization with decreasing or increasing fat mass on adipokines and inflammatory markers.

    Shadid S, Stehouwer CD, Jensen MD.

    J Clin Endocrinol Metab. 2006 Sep;91(9):3418-25. Epub 2006 Jun 27.PMID: 16804048 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    A randomized placebo-controlled study on the effects of pioglitazone on cortisol metabolism in polycystic ovary syndrome.

    Glintborg D, Hermann AP, Hagen C, Jensen LT, Frystyk J, Bennett P, Flyvbjerg A, Andersen M.

    Fertil Steril. 2009 Mar;91(3):842-50. Epub 2008 Apr 9.PMID: 18402944 [PubMed - indexed for MEDLINE]Related articles

    17.

    The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome.

    Yilmaz M, Bukan N, Ayvaz G, Karakoç A, Törüner F, Cakir N, Arslan M.

    Hum Reprod. 2005 Dec;20(12):3333-40. Epub 2005 Aug 25.PMID: 16123091 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome.

    Paradisi G, Steinberg HO, Shepard MK, Hook G, Baron AD.

    J Clin Endocrinol Metab. 2003 Feb;88(2):576-80.PMID: 12574183 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Oxidised low-density lipoprotein concentration - early marker of an altered lipid metabolism in young women with PCOS.

    Macut D, Damjanovic S, Panidis D, Spanos N, Glisic B, Petakov M, Rousso D, Kourtis A, Bjekic J, Milic N.

    Eur J Endocrinol. 2006 Jul;155(1):131-6.PMID: 16793959 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Effects of oral fat and glucose tolerance test on serum lipid profile, apolipoprotein, and CRP concentration, and insulin resistance in patients with polycystic ovary syndrome.

    Bahceci M, Aydemir M, Tuzcu A.

    Fertil Steril. 2007 Jun;87(6):1363-8. Epub 2007 Mar 23.PMID: 17362944 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity